← All trials
NCT06786429
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2026
- Primary completion
- Sep 30, 2030
- Completion date
- Sep 30, 2030
- First posted
- Jan 22, 2025
- Last posted
- Jan 31, 2025
- Enrollment
- 1800
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Eunice DubeLead sponsor
- National University of Science and Technology, ZimbabweCollaborator
- National University of Science and Technology, ZimbabweOfficial
- National Cancer Institute (NCI)Official
- Eunice DubeOfficial
- Eunice DubeSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.